Stock listing
BOATS:CGEN Compugen Ltd. Stock
US listing (BOATS) of Compugen Ltd. · home listing NASDAQ:CGEN
Follow Compugen Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CGEN
$1.84 USD -0.12 (-6.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CGEN
- Day range
- $1.81 – $1.88 USDNov 20, 2026
- Volume
- 188,249 sharesNov 20, 2026
- Market cap
- $174.3M USDAt the close on Nov 20, 2026 · price × 94.72M shares outstanding
- 52-week range
- $1.43 – $3.24 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $552,185 USDMedian day 198,865 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CGEN · Home | $1.84 USD | -0.12 (-6.1%) | 188,249 | $1.85 | $1.875 | $1.81 | $1.96 | Close on Nov 20, 2026 |
| TASE:CGEN | 645.00 ILA (agorot) | -11.10 (-1.7%) | 44,952 | 650.00 | 654.90 | 631.20 | 656.10 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CGEN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.84 | -0.12 | -6.1% | $1.85 | $1.875 | $1.81 | 188,249 | |
| $1.96 | -0.06 | -3.0% | $2.00 | $2.025 | $1.96 | 145,988 | |
| $2.02 | -0.02 | -1.0% | $1.99 | $2.05 | $1.98 | 197,679 | |
| $2.04 | -0.06 | -2.9% | $2.06 | $2.07 | $2.00 | 250,429 | |
| $2.10 | -0.02 | -0.9% | $2.11 | $2.12 | $2.035 | 209,585 | |
| $2.12 | +0.03 | +1.4% | $2.04 | $2.14 | $2.04 | 190,239 | |
| $2.09 | 0.00 | 0.0% | $2.09 | $2.115 | $2.07 | 210,994 | |
| $2.09 | -0.05 | -2.3% | $2.13 | $2.14 | $2.03 | 214,912 | |
| $2.14 | +0.18 | +9.2% | $1.96 | $2.15 | $1.96 | 290,494 | |
| $1.96 | +0.04 | +2.1% | $1.88 | $1.97 | $1.88 | 183,990 | |
| $1.92 | -0.11 | -5.4% | $2.00 | $2.00 | $1.865 | 299,927 | |
| $2.03 | +0.02 | +1.0% | $2.03 | $2.05 | $1.98 | 202,920 | |
| $2.01 | +0.03 | +1.5% | $1.98 | $2.04 | $1.98 | 212,668 | |
| $1.98 | 0.00 | 0.0% | $1.97 | $1.995 | $1.955 | 151,472 | |
| $1.98 | -0.06 | -2.9% | $2.02 | $2.02 | $1.92 | 255,458 | |
| $2.04 | +0.03 | +1.5% | $2.02 | $2.07 | $2.00 | 142,900 | |
| $2.01 | +0.04 | +2.0% | $1.96 | $2.01 | $1.96 | 149,264 | |
| $1.97 | +0.095 | +5.1% | $1.92 | $1.97 | $1.88 | 131,407 | |
| $1.875 | -0.065 | -3.4% | $1.95 | $1.975 | $1.87 | 334,463 | |
| $1.94 | -0.02 | -1.0% | $1.97 | $1.97 | $1.89 | 148,020 | |
| $1.96 | -0.16 | -7.5% | $2.11 | $2.14 | $1.92 | 285,545 | |
| $2.12 | -0.02 | -0.9% | $2.15 | $2.20 | $2.105 | 186,969 | |
| $2.14 | +0.17 | +8.6% | $1.96 | $2.18 | $1.96 | 923,298 | |
| $1.97 | +0.01 | +0.5% | $1.97 | $1.995 | $1.95 | 159,251 | |
| $1.96 | -0.12 | -5.8% | $2.08 | $2.09 | $1.93 | 173,435 | |
| $2.08 | +0.08 | +4.0% | $2.02 | $2.13 | $2.02 | 200,141 | |
| $2.00 | +0.02 | +1.0% | $2.01 | $2.02 | $1.95 | 378,142 | |
| $1.98 | -0.09 | -4.3% | $2.09 | $2.09 | $1.96 | 223,637 | |
| $2.07 | -0.06 | -2.8% | $2.13 | $2.13 | $2.07 | 86,472 | |
| $2.13 | +0.01 | +0.5% | $2.13 | $2.13 | $2.08 | 123,363 | |
| $2.12 | -0.03 | -1.4% | $2.14 | $2.16 | $2.04 | 243,151 | |
| $2.15 | -0.07 | -3.2% | $2.22 | $2.225 | $2.13 | 201,813 | |
| $2.22 | -0.09 | -3.9% | $2.32 | $2.331 | $2.205 | 265,380 | |
| $2.31 | 0.00 | 0.0% | $2.30 | $2.32 | $2.25 | 198,865 | |
| $2.31 | -0.03 | -1.3% | $2.34 | $2.38 | $2.305 | 113,986 | |
| $2.34 | -0.04 | -1.7% | $2.39 | $2.435 | $2.33 | 173,346 | |
| $2.38 | +0.03 | +1.3% | $2.35 | $2.41 | $2.345 | 118,236 | |
| $2.35 | +0.02 | +0.9% | $2.32 | $2.35 | $2.30 | 117,182 | |
| $2.33 | -0.05 | -2.1% | $2.34 | $2.345 | $2.315 | 94,071 | |
| $2.38 | +0.01 | +0.4% | $2.40 | $2.42 | $2.345 | 77,756 | |
| $2.37 | +0.03 | +1.3% | $2.34 | $2.375 | $2.325 | 111,364 | |
| $2.34 | -0.15 | -6.0% | $2.45 | $2.47 | $2.305 | 288,332 | |
| $2.49 | +0.055 | +2.3% | $2.46 | $2.495 | $2.405 | 230,978 | |
| $2.435 | -0.055 | -2.2% | $2.45 | $2.495 | $2.42 | 217,393 | |
| $2.49 | +0.03 | +1.2% | $2.47 | $2.49 | $2.45 | 128,001 | |
| $2.46 | +0.05 | +2.1% | $2.42 | $2.47 | $2.42 | 122,757 | |
| $2.41 | 0.00 | 0.0% | $2.41 | $2.47 | $2.40 | 117,641 | |
| $2.41 | -0.07 | -2.8% | $2.49 | $2.49 | $2.37 | 330,761 | |
| $2.48 | +0.01 | +0.4% | $2.42 | $2.54 | $2.42 | 144,471 | |
| $2.47 | +0.01 | +0.4% | $2.47 | $2.496 | $2.43 | 162,163 | |
| $2.46 | -0.02 | -0.8% | $2.48 | $2.51 | $2.44 | 206,983 | |
| $2.48 | -0.08 | -3.1% | $2.55 | $2.55 | $2.46 | 293,782 | |
| $2.56 | -0.03 | -1.2% | $2.55 | $2.625 | $2.55 | 192,901 | |
| $2.59 | +0.035 | +1.4% | $2.54 | $2.61 | $2.54 | 199,695 | |
| $2.555 | -0.075 | -2.9% | $2.64 | $2.66 | $2.535 | 163,617 | |
| $2.63 | +0.04 | +1.5% | $2.56 | $2.63 | $2.555 | 127,918 | |
| $2.59 | +0.03 | +1.2% | $2.56 | $2.60 | $2.53 | 168,925 | |
| $2.56 | -0.04 | -1.5% | $2.63 | $2.63 | $2.52 | 175,117 | |
| $2.60 | -0.16 | -5.8% | $2.72 | $2.72 | $2.58 | 228,794 | |
| $2.76 | -0.08 | -2.8% | $2.86 | $2.86 | $2.72 | 301,266 | |
| $2.84 | -0.03 | -1.0% | $2.83 | $2.935 | $2.80 | 667,034 | |
| $2.87 | +0.28 | +10.8% | $2.60 | $2.91 | $2.59 | 799,789 | |
| $2.59 | -0.025 | -1.0% | $2.58 | $2.605 | $2.49 | 218,360 | |
| $2.615 | -0.035 | -1.3% | $2.64 | $2.77 | $2.61 | 447,161 | |
| $2.65 | +0.21 | +8.6% | $2.54 | $2.68 | $2.47 | 993,918 |
- Ticker
- BOATS:CGEN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
Latest earnings call · Nov 9, 2026
Compugen (NASDAQ:CGEN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 33 slides
Latest news
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
Nov 10, 2026
Closed $2.09 (-2.3%) on Nov 10, 2026
Compugen Reports Third Quarter 2026 Results
Nov 9, 2026
Closed $2.14 (+9.2%) on Nov 9, 2026
Compugen to Participate in November Investor Conferences
Nov 3, 2026
Closed $2.01 (+1.5%) on Nov 3, 2026
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Oct 26, 2026
Closed $1.88 (-3.4%) on Oct 26, 2026
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
Oct 6, 2026
Closed $2.22 (-3.9%) on Oct 6, 2026
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
Sep 22, 2026
Closed $2.49 (+2.3%) on Sep 22, 2026
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $2.56 (-1.2%) on Sep 8, 2026
Compugen Reports Second Quarter 2026 Results
Aug 3, 2026
Closed $2.38 (+1.3%) on Aug 3, 2026
Compugen to Participate in BTIG Biotechnology Conference 2026
Jul 21, 2026
Closed $2.49 (+6.4%) on Jul 21, 2026
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
Jul 20, 2026
Closed $2.34 (-1.3%) on Jul 20, 2026
Compugen Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 195 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 9, 2026
- Decks
- 21 decks · latest Oct 5, 2026
Where Compugen Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CGEN · Home listing | NASDAQ | United States | USD |
| TASE:CGEN | TASE | Israel | ILA |
| BOATS:CGEN · This page | BOATS | United States | USD |
| Tradegate:CW9 | Tradegate | Germany | EUR |
Valuation
EV/sales 0.8× against a median of 15.6×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $59.55M USD
- P/E
- 4.8×
- EV/sales
- 0.8×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.1×
- Gross margin
- 86.2%
- Operating margin
- 41.3%
- Net margin
- 47.9%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Compugen Ltd. · NASDAQ:CGEN | US$174.3M | US$59.55M | 4.8× | 0.8× | n/a | 2.1× | 47.9% | 0.0× | 1.49 |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Nanexa AB · OMXSTO:NANEXA | US$175.1M | US$170.1M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591 | US$170.8M | US$39.93M | n/a | 2.1× | n/a | 1.2× | −259.6% | 0.2× | n/a |
| Entrada Therapeutics, Inc. · NASDAQ:TRDA | US$170.3M | US$24.60M | n/a | 6.2× | n/a | 0.9× | n/a | 0.2× | 1.43 |
| SinoMab Bioscience Ltd. · HKEX:3681 | US$166.3M | US$172.4M | n/a | n/a | n/a | 3.1× | n/a | 0.7× | n/a |
| Median of the others | US$175.9M | US$115.6M | 15.6× | 2.1× | −228.9% | 0.1× | 1.35 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.80 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.29 · 2 analysts
- Revenue, year to Dec 2026
- 9.56M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Eran Ophir | President and CEO |
| David Silberman | Chief Financial Officer |
| Pierre Ferre | Chief Operating Officer |
| Eran Ben Dor | General Counsel and Corporate Secretary |
| Lindsey Trickett | Head of Investor Relations and Corporate Communications |
| Yvonne Naughton | Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail |
| Dorit Amitay | Vice President, Human Resources |
| Sharon Kredo-Russo | Senior Vice President, Research & Discovery |
| Zurit Levine | Senior Vice President, Business Development |
| Anat Cohen-Dayag | Executive Chair |
| Eran Perry | Managing Director and Chairman of the Investment Committee, MII Fund & Labs |
| Michelle Mahler | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Anat Cohen-Dayag | Executive Chair |
| Eran Ophir | President and CEO |
| Michele Holcomb | Director |
Events
- Next results
- Mar 1, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Compugen (NASDAQ:CGEN) Q3 2026 Earnings Call | Mon, Nov 09, 2026 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q2 2026 Earnings Call | Mon, Aug 03, 2026 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q1 2026 Earnings Call | Mon, May 18, 2026 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q4 2025 Earnings Call | Mon, Mar 02, 2026 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q3 2025 Earnings Call | Thu, Nov 20, 2025 · 5:00 PM ET | Replay |
| Compugen (NASDAQ:CGEN) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q1 2025 Earnings Call | Mon, May 19, 2025 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Compugen (NASDAQ:CGEN) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 8:30 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +9.2% |
| Q2 2026 | Aug 3, 2026 · Before open | +1.3% |
| Q1 2026 | May 18, 2026 · Before open | +4.0% |
| Q4 2025 | Mar 2, 2026 · Before open | +24.3% |
| Q3 2025 | Nov 10, 2025 · Before open | +3.1% |
| Q2 2025 | Aug 6, 2025 · Before open | 0.0% |
| Q1 2025 | May 19, 2025 · Before open | 0.0% |
| Q4 2024 | Mar 4, 2025 · Before open | −7.2% |
| Q3 2024 | Nov 12, 2024 · Before open | −8.1% |
| Q2 2024 | Aug 6, 2024 · Before open | +4.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 20, 2024 · Before open | −17.5% |
| Q4 2023 | Mar 5, 2024 · Before open | −13.6% |
| Q3 2023 | Nov 7, 2023 · Before open | −5.8% |
| Q2 2023 | Aug 7, 2023 · Before open | −8.0% |
| Q1 2023 | May 15, 2023 · Before open | +10.0% |
| Q4 2022 | Feb 27, 2023 · Before open | +2.2% |
| Q3 2022 | Nov 14, 2022 · Before open | −9.3% |
| Q2 2022 | Aug 4, 2022 · Before open | −4.3% |
| Q1 2022 | May 16, 2022 · Before open | +1.6% |
| Q4 2021 | Feb 24, 2022 · Before open | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 33 slides | Oct 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 7 slides | Aug 3, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 50 slides | Mar 2, 2026 |
| Technical Presentation (May 2023) | Technical | 19 slides | May 23, 2023 |
| Investor Presentation (May 2023) | Investor deck | 7 slides | May 15, 2023 |
| CIMT Annual Meeting 2023 | Conference | 16 slides | May 5, 2023 |
| TIGIT Axis Therapies Digital Summit 2022 | Conference | 31 slides | Dec 8, 2022 |
| Keystone Symposium, Decoding the Cancer Immunity Interactome 2022 | Conference | 22 slides | March 2022 |
| Investor Presentation (February 2022) | Investor deck | 33 slides | February 2022 |
| Q3 2021 Earnings Presentation | Earnings | 12 slides | Nov 12, 2021 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SITC Targets for Cancer Immunotherapy: A Deep Dive Seminar Series (June 2021) | Conference | 19 slides | Jun 29, 2021 |
| Investor Presentation (November 2020) | Investor deck | 36 slides | November 2020 |
| Technical Presentation (April 2020) | Technical | 24 slides | Apr 27, 2020 |
| Investor Presentation (June 2016) | Investor deck | 47 slides | June 2016 |
| Investor Presentation (September 2015) | Investor deck | 37 slides | September 2015 |
| Investor Presentation (March 2006) | Investor deck | 24 slides | March 2006 |
| Investor Presentation (May 2005) | Investor deck | 29 slides | May 2005 |
| R&D Leaders' Forum Autumn 2004 | Conference | 26 slides | October 2004 |
| Bio-Tech Israel 2004 | Conference | 17 slides | May 5, 2004 |
| Investor Presentation (February 2004) | Investor deck | 28 slides | February 2004 |
| RDLeaders Forum 2004 | Conference | 30 slides | 2004 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.8M | 27.9M | 33.5M | 7.50M | 6.00M | 2.00M | 0 | 17.8M | 0 | 712.0K |
| Cost of revenue | 9.25M | 7.93M | 2.00M | 975.0K | 680.0K | 60.0K | 989.0K | 1.03M | 1.59M | 223.0K |
| Gross profit | 63.5M | 19.9M | 31.5M | 6.53M | 5.32M | 1.94M | -989.0K | 16.8M | -1.59M | 489.0K |
| Research and development | 22.8M | 24.8M | 34.5M | 30.6M | 28.7M | 22.8M | 19.8M | 30.3M | 28.6M | 24.5M |
| Selling, general and administrative | 8.89M | 9.44M | 9.73M | 10.3M | 10.9M | 9.80M | 8.41M | 8.04M | 7.63M | 7.35M |
| Operating income | 31.3M | -14.9M | -13.0M | -35.4M | -35.1M | -31.5M | -28.9M | -23.2M | -37.4M | -32.6M |
| Depreciation and amortization | 475.0K | 486.0K | 476.0K | 482.0K | 461.0K | 715.0K | 989.0K | 1.39M | 1.59M | 1.48M |
| EBITDA | 31.8M | -14.4M | -12.5M | -34.9M | -34.6M | -30.8M | -27.9M | -21.8M | -35.8M | -31.1M |
| Interest expense | 34.0K | 31.0K | 27.0K | 869.0K | 1.72M | 1.81M | 620.0K | 508.0K | 705.0K | |
| Income before tax | 35.4M | -9.71M | -9.78M | -33.6M | -34.2M | -29.7M | -28.1M | -22.6M | -37.1M | -31.5M |
| Income tax | 54.0K | 4.52M | 8.97M | 58.0K | 0 | 0 | -722.0K | -1.26M | -678.0K | 20.0K |
| Net income | 35.3M | -14.2M | -18.8M | -33.7M | -34.2M | -29.7M | -27.3M | -22.6M | -37.1M | -31.5M |
| Earnings per share, basic | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 | -0.37 | -0.43 | -0.41 | -0.72 | -0.62 |
| Earnings per share, diluted | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 | -0.37 | -0.43 | -0.41 | -0.72 | -0.62 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 90.6M | 18.2M | 13.9M | 11.1M | 7.80M | 7.14M | 9.19M | 5.86M | 25.5M | 9.71M |
| Short-term investments | 9.28M | 23.6M | 11.7M | 0 | 109.2M | 116.6M | 34.0M | 39.2M | 3.92M | 50.8M |
| Receivables | 294.0K | 0 | 61.0M | 0 | 188.0K | 2.00M | 341.0K | 167.0K | 741.0K | 82.0K |
| Inventory | -72.6M | -5.99M | -119.3M | -780.0K | -1.34M | -1.74M | -2.06M | |||
| Current assets | 148.0M | 106.0M | 114.6M | 86.1M | 123.2M | 129.1M | 45.0M | 46.6M | 31.2M | 62.7M |
| Property, plant and equipment | 681.0K | 852.0K | 1.22M | 1.53M | 1.66M | 1.71M | 2.34M | 3.37M | 4.65M | 5.96M |
| Total assets | 156.6M | 115.0M | 121.3M | 94.2M | 132.2M | 138.3M | 53.8M | 53.2M | 38.7M | 71.1M |
| Accounts payable | 2.35M | 1.84M | 3.50M | 1.77M | 4.62M | 1.41M | 1.09M | 2.95M | 3.44M | 1.27M |
| Current liabilities | 22.6M | 20.2M | 26.3M | 11.9M | 17.1M | 10.5M | 6.82M | 9.99M | 6.19M | 4.74M |
| Long-term debt | 3.00M | |||||||||
| Total debt | 2.96M | 2.91M | 1.35M | 1.93M | 2.75M | 3.17M | 3.58M | |||
| Total liabilities | 53.8M | 60.1M | 55.8M | 16.5M | 25.5M | 18.5M | 15.4M | 15.9M | 9.45M | 7.62M |
| Shareholders' equity | 102.7M | 54.9M | 65.6M | 77.7M | 106.7M | 119.8M | 38.3M | 37.2M | 29.3M | 63.5M |
| Shares outstanding | 94.6M | 89.5M | 89.2M | 86.6M | 86.4M | 83.7M | 67.9M | 59.8M | 51.3M | 51.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 31.6M | 49.6M | -35.9M | -34.1M | -22.7M | -28.3M | -27.9M | -13.3M | -30.7M | -19.8M |
| Capital spending | -306.0K | -118.0K | -172.0K | -477.0K | -292.0K | -166.0K | -155.0K | -158.0K | -385.0K | -2.60M |
| Free cash flow | 31.3M | 49.5M | -36.1M | -34.6M | -23.0M | -28.5M | -28.0M | -13.4M | -31.0M | -22.4M |
| Cash from investing | 30.0M | -46.3M | 35.5M | 37.1M | 6.62M | -82.2M | 5.33M | -35.2M | 46.3M | 16.2M |
| Cash from financing | 10.6M | 554.0K | 3.08M | 353.0K | 16.8M | 108.5M | 25.9M | 28.4M | 201.0K | 2.46M |
| Share buybacks | 25.9M | 28.4M | 201.0K | 2.46M | ||||||
| Change in cash | 72.4M | 3.97M | 2.83M | 2.91M | 704.0K | -2.03M | 3.37M | -20.1M | 15.8M | -1.15M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 10, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | Aug 4, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 608 filings. Open Filings
Cap table
Built by 6ix from Compugen Ltd.’s releases
- Common shares
- 94,724,146
- Fully diluted
- 94,724,146
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 94,724,146 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 94,724,146 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sanford S Zweifach Other companies: Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); ESSA Pharma Inc (Director · Oct 1, 2020 – Mar 25, 2024 · Past); Anthera Pharmaceuticals Inc (Director · Mar 25, 2013 – May 21, 2015 · Past) | Director · Since at least Mar 18, 2026 |
| David Silberman Other companies: Nasus Pharma Ltd. (Board Member · Since at least Mar 18, 2026); Oramed Pharmaceuticals Inc. (Chief Financial Officer · Jul 5, 2021 – Jan 4, 2024 · Past) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Michele Holcomb Other companies: Kimball Electronics, Inc. (Director · Since at least Nov 7, 2019); Cardinal Health, Inc. (EVP - Strategy & Corp. Dev. · Jan 3, 2017 – Aug 15, 2022 · Past) | Director · Since at least Feb 12, 2026 |
| Anat Cohen-Dayag Other companies: Gamida Cell Ltd (Director · Jan 28, 2022 – Feb 8, 2023 · Past) | Executive Chair · Since at least Mar 2, 2026 |
| Dorit Amitay | Vice President, Human Resources · Since at least Nov 5, 2026 |
| Eran Ben Dor | General Counsel and Corporate Secretary · Since at least Nov 5, 2026 |
| Eran Ophir | President and CEO · Since at least Mar 18, 2026 |
| Eran Perry | Managing Director and Chairman of the Investment Committee, MII Fund & Labs · Since at least Mar 18, 2026 |
| Gilead Halevy | Director · Since at least Mar 18, 2026 |
| Lindsey Trickett | Head of Investor Relations and Corporate Communications · Since at least Nov 3, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Mathias Hukkelhoven | Director · Since at least Jul 29, 2026 |
| Michelle Mahler | Chief Medical Officer · Since at least Mar 18, 2026 |
| Pierre Ferre | Chief Operating Officer · Since at least Mar 18, 2026 |
| Russo Sharon Kredo | SVP, Research & Discovery · Since at least Mar 18, 2026 |
| Savitzky Kinneret Livnat | Director · Since at least Mar 18, 2026 |
| Sharon Kredo-Russo | Senior Vice President, Research & Discovery · Since at least Nov 5, 2026 |
| Yvonne Naughton | Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail · Since at least Dec 17, 2025 |
| Zurit Levine | Senior Vice President, Business Development · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about Compugen Ltd.